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ORIGINAL RESEARCH
Rheumatic Heart Disease in the United 
States: Forgotten But Not Gone
Results of a 10 Year Multicenter Review
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BACKGROUND: Recent evaluation of rheumatic heart disease (RHD) mortality demonstrates disproportionate disease burden 
within the United States. However, there are few contemporary data on US children living with acute rheumatic fever (ARF) 
and RHD.
METHODS AND RESULTS: Twenty- two US pediatric institutions participated in a 10- year review (2008– 2018) of electronic medical 
records and echocardiographic databases of children 4 to 17 years diagnosed with ARF/RHD to determine demographics, 
diagnosis, and management. Geocoding was used to determine a census tract- based socioeconomic deprivation index. 
Descriptive statistics of patient characteristics and regression analysis of RHD classification, disease severity, and initial anti-
biotic prescription according to community deprivation were obtained. Data for 947 cases showed median age at diagnosis 
of 9 years; 51% and 56% identified as male and non- White, respectively. Most (89%) had health insurance and were first diag-
nosed in the United States (82%). Only 13% reported travel to an endemic region before diagnosis. Although 96% of patients 
were prescribed secondary prophylaxis, only 58% were prescribed intramuscular benzathine penicillin G. Higher deprivation 
was associated with increasing disease severity (odds ratio, 1.25; 95% CI, 1.08– 1.46).
CONCLUSIONS: The majority of recent US cases of ARF and RHD are endemic rather than the result of foreign exposure. 
Children who live in more deprived communities are at risk for more severe disease. This study demonstrates a need to 
improve guideline- based treatment for ARF/RHD with respect to secondary prophylaxis and to increase research efforts to 
better understand ARF and RHD in the United States.
Key Words: acute rheumatic fever ■ deprivation ■ pediatric ■ rheumatic heart disease ■ socioeconomic status ■ United States
Worldwide, rheumatic heart disease (RHD) re-mains one of the most common cardiovascu-lar diseases with 40.5 million prevalent cases resulting in ≈305 000 deaths annually.
1– 3 Acute rheu-
matic fever (ARF) incidence and RHD prevalence vary 
greatly across the globe, occurring most commonly 
Correspondence to: Sarah R. de Loizaga MD, MMSc, 3333 Burnet Ave MLC 2003, Cincinnati, OH 45229. E- mail: sarah.deloizagacarney@cchmc.org
*University of Cincinnati, OH, was not a participating institution.
†Meghan Zimmerman’s current affiliation is Dartmouth Hitchcock Medical Center, Lebanon, NH
Supplementary Material for this article is available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.120.020992
For Sources of Funding and Disclosures, see page 11.
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative 
Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non- commercial and no modifications or adaptations are made. 




 http://ahajournals.org by on Septem
ber 9, 2021
J Am Heart Assoc. 2021;10:e020992. DOI: 10.1161/JAHA.120.020992 2
de Loizaga et al RHD in the United States 10- Year Review
in low- and middle- income countries.2 Although ARF 
was the leading cause of mortality in 5- to 20- year- olds 
in the United States during the 1920s, the annual in-
cidence of ARF in the United States today is low (<2 
cases per 100  000 school- aged children compared 
with up to 150 cases per 100  000 worldwide).4– 6 
These data may lead to the conclusions that ARF and 
RHD are diseases of the past in the United States and 
other high- income countries. However, this view does 
not take persistent inequities into account. Recent 
geographic evaluation based on RHD mortality has 
demonstrated pockets of disproportionate disease 
burden; some coincide with elevated rates of poverty 
and disadvantage, but this is not true in all regions.7,8 
As mortality captures only a fraction of those affected 
by RHD and lags behind diagnosis by decades, it fails 
to accurately capture children currently affected by this 
disease. There is little contemporary data on children 
living with ARF and RHD within the United States. The 
role socioeconomic status plays in current pediatric 
cases is similarly unknown. This study describes the 
demographics, clinical features, and cardiac involve-
ment of pediatric ARF/RHD in the United States over 




Sixty US institutions (including all 59 Accreditation 
Council for Graduate Medical Education accredited 
cardiology fellowship programs) were invited to partici-
pate in a 10- year review (2008– 2018) of the electronic 
medical record and echocardiography databases 
of pediatric patients ages 4 to 17 with a diagnosis of 
ARF or RHD. Patients with congenital heart disease 
were excluded. Diagnostic International Classification 
of Diseases, Ninth Revision and Tenth Revision (ICD- 
9, ICD- 10) codes were used to identify children with 
ARF and RHD in both the inpatient and outpatient set-
ting. Primary institutional review board approval was 
obtained from Cincinnati Children’s Hospital Medical 
Center, and all participating centers also received sec-
ondary institutional review board approval except for 1 
institution that relied on Cincinnati Children’s Hospital 
Medical Center institutional review board. The de- 
identified data that support the findings of this study 
are available on request from the corresponding author 
with appropriate human subject protections assured.
Patient Characteristics and Operational 
Definitions for Key Outcomes
Electronic medical record chart abstraction and re-
view of echocardiographic databases enabled gather-
ing demographic characteristics, presenting features, 
echocardiographic findings at presentation, and treat-
ment with secondary antibiotic prophylaxis. Apart from 
changes in antibiotic regimens for secondary prophy-
laxis, data focused on features at time of presentation 
and did not collect longitudinal data. Study data were 
collected and managed using REDCap electronic data 
capture tools hosted at Cincinnati Children’s Hospital 
Medical Center.9,10 Echocardiographic data was gath-
ered from nonstandardized reports at each center; no 
images were reviewed, and no components were in-
dependently reclassified.
Disease Severity
Based upon the echocardiographic findings at pres-
entation, subjects were classified as having either mild, 
moderate, or severe disease (Table 1). If the mitral and 
aortic valve were affected in varying degrees, the more 
significant pathology was used to define overall dis-
ease severity.
Appropriate Secondary Prophylaxis
For this study, as recommended by the American 
Heart Association and other international guidelines, 
benzathine penicillin G (BPG) was considered the 
CLINICAL PERSPECTIVE
What Is New?
• This article characterizes recent pediatric cases 
of acute rheumatic fever and rheumatic heart 
disease in the United States, the majority of 
which are endemic.
• Although most children with acute rheumatic 
fever/rheumatic heart disease are receiving 
echocardiograms and secondary prophylaxis, 
only about half are receiving benzathine penicil-
lin G, the gold standard.
What Are the Clinical Implications?
• Children living in deprived communities are at 
risk for more severe disease; increased research 
is needed to understand and care for children in 
the United States at highest risk of acute rheu-
matic fever and rheumatic heart disease.
Nonstandard Abbreviations and Acronyms
ARF acute rheumatic fever
BPG benzathine penicillin G
DI deprivation index
RHD rheumatic heart diseaseD
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gold standard for RHD prophylaxiss.11– 13 Based on a 
subject’s disease classification at presentation (ARF 
versus RHD) in addition to echocardiographic findings 
at presentation, subjects were classified in accord-
ance with the American Heart Association guide-
lines for secondary prophylaxis duration (Table 2).11 If 
the recommended duration of antibiotic prophylaxis 
was less than that advised by the American Heart 




An endemic region was defined as a country with an 
“estimated childhood mortality secondary to RHD >0.15 
deaths per 100  000 population among children 5 to 
9 years old,” as defined by the Global Burden of Disease.2 
Travel exposure was determined by any documented 
travel before diagnosis as noted in the medical record. 
Given limitations of the electronic medical record, time 
spent in the endemic region could not be determined.
Deprivation Index
The previously published deprivation index (DI) was em-
ployed to capture community socioeconomic context.14 
Using Health Insurance Portability and Accountability 
Act- compliant software, the street address for each 
subject was geocoded to a corresponding census 
tract. The related tract was characterized by the DI, enu-
merated using 6 variables related to material deprivation 
obtained from the 2015 American Community Survey: 
(1) fraction of population with income in past 12 months 
below poverty level, (2) median household income in 
past 12  months in 2015 inflated- adjusted dollars, (3) 
fraction of population 25 and older with educational at-
tainment of at least high school graduation (includes 
general educational development equivalency), (4) frac-
tion of population with no health insurance coverage, 
(5) fraction of households receiving public assistance 
income or food stamps or Supplemental Nutrition 
Assistance Program in the past 12 months, and (6) frac-
tion of houses that are vacant. The DI ranges from 0 to 
1, with 1 reflecting the greatest community deprivation. 
Whereas the DI is a measure of community deprivation, 
census tracts tend to be homogenous and therefore 
served as reasonable proxy for individual (or house-
hold) deprivation. Geocoding and DI derivation was 
completed at Cincinnati Children’s using Decentralized 
Geomarker Assessment for Multi- Site Studies,14 except 
for 2 institutions who performed their own geocoding 
on site using the same software.
Statistical Analysis
Descriptive statistics were used to enumerate the dis-
tribution of key variables. Independent sample t tests 
and chi- square tests were used to test for differences 
in participant characteristics according to disease clas-
sification, disease severity, and DI dichotomized at the 
national average. Fisher’s exact tests are reported for 
categorical variables where the expected cell counts do 
not exceed 5 in more than 80% of cells. Multivariable 
logistic regression was used to obtain odds ratios (ORs) 
and 95% CIs for RHD classification at presentation ac-
cording to a 1 SD increase in participant DI. Ordinal lo-
gistic regression (cumulative logit) was used to obtain 
an OR for increasing disease severity (mild, moderate, 
severe). Multinomial logistic regression was used to 
obtain ORs for initial antibiotic prescription. Covariates 
thought to potentially confound the association be-
tween the DI and outcomes of interest were selected 
a priori and included biological sex, age at diagnosis, 
race, ethnicity, and insurance type. The percentage of 
missing values across the variables considered for re-
gression ranged from 0% to 12%. Incomplete variables 
were multiply imputed (n=50 data sets) using full condi-
tional specification as implemented by the default set-
tings in mice version 3.9.0.15 Variables entered into the 
imputation model included sex, age at diagnosis, race, 
ethnicity, insurance type, DI, RHD classification, RHD 
severity, and initial antibiotic prescription. Estimates 
were obtained for each imputed data set using the base 
R logistic regression (glm), MASS version 7.3.5116 polr, 
and nnet version 7.3.1416 multinomial logistic regression 
functions and combined using Rubin’s rules. Potential 
nonlinear associations were examined using restricted 
cubic splines but not retained as inclusion of addi-
tional terms did not improve model fit as determined 
by the Akaike information criterion. Therefore, ORs are 
presented in all models for a 1 SD change in the DI. 
Analyses were conducted using R version 4.0.0,17 JMP 
Version 14.0 (Cary, NC), and STATA MP version 13.0 
(College Station, TX).
Table 1. Disease Severity Based on Severity of Cardiac Involvement at Time of Presentation
Mitral or Aortic Regurgitation Left Ventricular Dysfunction Mitral Stenosis
Mild or no cardiac involvement Normal, trivial, or mild … …
Moderate cardiac involvement Mild to moderate, Moderate None or mildly diminished …
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RESULTS
Participant Characteristics
Data were collected for 947 children from 22 insti-
tutions (37% participation); enrollment by site varied 
significantly (from 7 to 132 subjects) (Table  S1 and 
Figure S1). Across all cases, the median age at di-
agnosis was 9 years (interquartile range 7– 12), with 
half identifying as male (487, 51%) and three- quarters 
identifying as non- Hispanic (700, 74%). Almost half 
identified as White (420, 44%). Most spoke English 
as their primary language (792, 84%) or had a parent 
who spoke English as a primary language (609, 82%). 
The majority of children had health insurance (846, 
89%), with slightly over half covered by Medicaid or 
Medicare (450, 53%). Subjects were largely diag-
nosed in the United States (82%), rather than abroad 
(Table 3).
Travel Exposure
Only 124 (13%) had known travel to an endemic region 
before diagnosis of ARF/RHD. The most frequently 
identified regions included the Pacific Islands (58, 37%) 
and Africa (33, 21%) (Figure). Those with RHD at time 
of diagnosis were more likely to report travel to an en-
demic region compared with those who presented 
with ARF (P=0.02; Table 3).
Presentation
Clinical Findings in Acute Rheumatic Fever
At time of presentation, nearly three- quarters of 
cases were diagnosed at the time of ARF (684, 
72%). The most commonly cited major Jones crite-
ria were carditis (336, 49%), polyarthritis (208, 30%), 
and Sydenham chorea (254, 37%), whereas the 
most commonly cited minor criteria were fever (330, 
48%) and elevated inflammatory markers (315, 46%) 
(Table 4). Of these, 96% had an echocardiogram per-
formed with the most common pathological findings 
of mitral regurgitation (417, 64%) and aortic regurgita-
tion (221, 34%). Rarely was there associated left ven-
tricular (10, 1.5%) or right ventricular (2, 0.3%) systolic 
dysfunction (Table 5).
Clinical Findings in Chronic Rheumatic 
Heart Disease
Having missed the diagnosis of ARF, 27% (258) were 
diagnosed with chronic RHD as their first presenta-
tion. Of these, one- third (35%) recalled a previous his-
tory consistent with ARF, though the diagnosis was 
not made. All had an echocardiogram. As in ARF, mi-
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(131, 51%) were the most common pathological find-
ings. Mitral stenosis was found in 19% of patients 
(Table 5).
Disease Severity
Disease severity was determined for the 872 partici-
pants who had echocardiographic data, of which 452 
(52%) had mild disease, 188 (22%) had moderate dis-
ease, and 232 (27%) had severe disease. Those who 
identified their race as White had less severe disease 
(P<0.001); there was no difference in disease sever-
ity with respect to ethnicity (Hispanic or Latino versus 
non- Hispanic or Latino, P=0.79). Possessing health in-
surance and type of health insurance (commercial ver-
sus public) were not associated with disease severity 
(P=0.51 and P=0.55, respectively). Severe disease was 
more likely if either the subject or subject’s parental pri-
mary language was not English (P=0.001 and P=0.047, 





Disease (n=258) P value
Sex 0.048
Male 487 (51.4%) 365 (53.4%) 119 (46.1%)
Female 460 (48.6%) 319 (46.6%) 139 (53.9%)
N=904 N=661 N=239
Age at diagnosis, y, median (interquartile range) 9 (7– 12) 9 (7– 12) 10 (7– 13) 0.001
Race <0.001
American Indian or Alaska Native 39 (4.1%) 22 (3.2%) 17 (6.6%)
Asian 43 (4.5%) 26 (3.8%) 17 (6.6%)
Black 172 (18.1%) 98 (14.3%) 73 (28.3%)
Native Hawaiian or other Pacific Islander 65 (6.9%) 39 (5.7%) 26 (10.1%)
White 420 (44.4%) 354 (51.8%) 63 (24.4%)
Other 143 (15.1%) 101 (14.8%) 41 (15.9%)
Unknown 65 (6.9%) 44 (6.4%) 21 (8.1%)
Ethnicity 0.83
Hispanic or Latino 161 (17.0%) 115 (16.8%) 46 (17.8%)
Non- Hispanic or Latino 700 (74.0%) 503 (73.5%) 193 (74.8%)
Unknown 85 (9.0%) 66 (9.6%) 19 (7.4%)
Primary language <0.001
English 792 (83.6%) 595 (87.0%) 193 (74.8%)
Spanish 82 (8.7%) 54 (7.9%) 28 (10.9%)
Other 62 (6.5%) 26 (3.8%) 35 (13.6%)
Unknown 11 (1.2%) 9 (1.3%) 2 (0.8%)
Has health insurance 846 (89.3%) 612 (89.5%) 229 (88.8%) 0.22
N=846 N=612 N=229
Type of health insurance 0.004
Private 344 (40.7%) 267 (43.6%) 75 (29.1%)
Medicaid or Medicare 450 (53.2%) 304 (49.7%) 144 (55.8%)
Both 3 (0.4%) 1 (0.2%) 0 (0%)
Unknown 49 (5.8%) 40 (6.5%) 10 (3.9%)
Diagnosed in the United States <0.001
Yes 780 (82.4%) 599 (87.6%) 177 (68.6%)
No 119 (12.6%) 52 (7.6%) 66 (25.6%)
Unknown 48 (5.1%) 33 (4.8%) 15 (5.8%)
N=747 N=543 N=256
Parent primary language English 609 (81.5%) 462 (85.1%) 193 (74.8%) <0.001
Prior travel to endemic region 124 (13.0%) 53 (7.7%) 70 (27.1%) 0.02
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respectively) compared with subjects whose primary 
language was English (Table 6).
Management
Secondary Prophylaxis
Although almost all patients were prescribed sec-
ondary prophylaxis (913, 96%), only half (527, 58%) 
were prescribed intramuscular benzathine penicillin G 
(BPG); 318 (35%) received oral penicillin and 68 (7%) 
were prescribed other antibiotics (Table 4). Subjects 
with no insurance or public insurance were more likely 
to receive BPG therapy versus oral therapy (62% and 
64%, respectively, versus 53% for private insurance, 
P=0.01). Although the reason for choosing oral antibi-
otics over BPG was known in fewer than half the cases 
(144, 39%), patient or family preference was the most 
commonly cited reason (107, 74%), followed by patient 
allergy (32, 22%). The type of secondary prophylaxis 
was changed in 18% (171) of subjects, with 7% (13) 
switching from initial nonpenicillin prophylaxis to peni-
cillin prophylaxis. In these cases, patients frequently 
had a preceding documented allergy to penicillin, but 
after further evaluation (often by allergy/immunology), 
the patient was cleared to receive penicillins and thus 
transitioned to BPG.
Duration of Prophylaxis
Seventeen percent of patients were advised a pro-
phylactic duration shorter than the American Heart 
Association guidelines recommend (Table 2).
Deprivation Index
The DI was calculated for 871 (92%) of cases. Of the 76 
addresses that could not be geocoded, the address 
was either missing (3), international (2), a PO box (44), 
listed as general delivery (1), or not recognized (26). The 
mean DI in our cases was 0.39±0.15, slightly higher 
than the national population- weighted mean DI of 0.37 
for those <18  years old.18 Using the national mean 
DI of 0.375, cases were assigned to a less deprived 
(DI <0.375) and more deprived (DI ≥0.375) group. 
Comparing characteristics between these groups dem-
onstrated that increased community deprivation was 
associated with identifying as non- White (66% versus 
42%, P<0.001), Hispanic- or Latino ethnicity (25% ver-
sus 11%, P<0.001), less frequently speaking English as 
a primary language (76% versus 90%, P<0.001), hav-
ing Medicaid or Medicare insurance (70% versus 34%, 
P<0.001), and less likely to be diagnosed in the United 
States (79% versus 85%, P=0.008). Higher deprivation 
was associated with increasing disease severity (OR, 
1.25; 95% CI, 1.08– 1.46) and higher likelihood of BPG 
when compared with enteral penicillin prescription 
(OR, 0.67; 95% CI, 0.56– 0.8) in models adjusted for 
participant sex, age at diagnosis, race, ethnicity, and 
insurance type (Table 7).
DISCUSSION
Through a 10- year retrospective case review, our 
data capture the contemporary picture of pediatric 
ARF and RHD in the United States. The use of pri-
mary source data, not previously employed at a na-
tional level, has allowed a more comprehensive and 
nuanced look at these cases. The addition of depri-
vation index highlights that ARF and RHD continue 
as diseases of health inequity, with children living in 
more deprived communities at increased risk of se-
vere RHD.
Caution must be employed when interpreting the 
demographics of our cases. Although our sample is 
large, it was not collected in a representative man-
ner and may not reflect the demographics of children 
with ARF/RHD living in the United States as a whole. 
Still, it is worth noting that there was a higher than ex-
pected percentage of children identifying as Black, or 
Indigenous (American Indian or Alaskan Native and 
Native Hawaiian or other Pacific Islander), which is 
consistent with previously reported increased risk for 
both population subgroups within the United States,5,6 
as well as the increased risk seen in Indigenous pop-
ulations in Australia, New Zealand, and Canada.19– 22 
Combined, these data suggest that more intensive 
surveillance, including active screening, could help 
characterize and develop plans to mitigate the risk in 
these vulnerable US communities.
It is also worth noting, that the majority of children 
diagnosed with ARF or RHD were diagnosed in the 
United States (>80%), spoke English as their primary 
language (>80%), and had health insurance (nearly 
Figure 1. Travel exposure.
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90%). Furthermore, 87% had no travel history to an 
endemic region, indicating a continued domestic bur-
den of ARF and RHD. This has important implications 
for provider awareness and appropriate use of primary 
and secondary prevention. Additionally, the continued 
domestic case burden highlights that diagnosis and 
treatment of symptomatic streptococcal sore throat 
can never prevent all cases of ARF. A group A strepto-
coccal vaccine, in contrast, could help eliminate new 
cases of ARF both here and around the world.13,23,24
This study also gives important insight into the clini-
cal presentation of ARF and RHD in the United States. 
Chorea was exceedingly common in this population 
(37% of those presenting with ARF), as compared with 
the <10% to 30% of ARF cases globally,25– 33 includ-
ing recent studies in the United States.5,6 It will be im-
portant in future studies to determine if high rates of 
chorea reflect true distribution of ARF presentations 
or if more mild joint presentations are being missed, 
skewing the percentages higher for chorea as a pri-
mary presentation.
Another important clinical finding is that a signifi-
cant number of children captured through this study 
presented with chronic RHD, one- quarter with severe 
disease, who may require cardiac catheterization or 
surgery in the future. Late presentation results in the 
missed opportunity to have maximum benefit from 
secondary antibiotic prophylaxis, which prevents group 
A streptococcal infections and recurrent ARF. Further 
research should be undertaken to study provider and 
parent awareness of ARF, as education might improve 
early ARF diagnosis and reduce the number of children 
presenting with late stage RHD.
These data highlight the successful implementa-
tion of evidence- based diagnostic recommendations 
for ARF and RHD in the United States. As newly rec-
ommended by the 2015 Jones criteria, children in this 
study were exceedingly likely to have had an echocar-
diogram as part of their diagnostic work- up (97%). As 
half of these cases predate these recommendations, 
high rates of echocardiography may also reflect the 
near universal access to echocardiography in US 
tertiary facilities (where case recruitment occurred). 
However, there was inconsistent reporting of echo-
cardiographic findings and frequent use of nonstan-
dardized definitions for grading severity of valvular and 
features of RHD. Future emphasis should be placed 
on standardization of echocardiographic evaluation for 
children with RHD including the American Society of 
Echocardiography and American Heart Association 
guidelines,34– 36 the revised Jones criteria from 2015,26 
and the 2012 World Heart Federation Guidelines for 
the Echocardiographic Diagnosis of Rheumatic Heart 
Disease37 to allow for a unified definition and ability to 
compare data across countries and continents using a 
standardized criteria for RHD diagnosis.
There was also substantial variation from guideline- 
based care on the type and duration of secondary pro-
phylaxis.11 Despite the fact that BPG is recommended 
as first- line prevention, having greater efficacy than 
oral penicillin in preventing recurrent ARF,12,13 only 58% 
of the cases was prescribed BPG. Family preference 
was the most common reason cited for not prescrib-
ing BPG. It is worth noting that those living in more 
deprived areas were more likely to be prescribed BPG 
than oral penicillin, perhaps perceived by clinicians to 
be at higher risk. Our data highlight variability in the 
recommended duration of secondary prevention, 
Table 4. Presentation at Diagnosis and Management




Sydenham chorea 254 (37.1%)
Subcutaneous nodules 24 (3.5%)
Erythema marginatum 59 (8.6%)
Minor criteria
Fever 330 (48.2%)
Elevated C- reactive protein and/or erythrocyte 
sedimentation rate
315 (46.1%)







Initial antibiotic choice for secondary prophylaxis  
(n=913, prescribed secondary prophylaxis)
BPG, intramuscular 527 (57.7%)





Reason for not using BPG  
(n=370, prescribed a known alternate)
Patient/family preference 107 (28.9%)
Patient allergy 32 (8.6%)
Other 5 (1.4%)
Unknown 226 (61.1%)
Secondary prophylaxis prescription changed  
(n=913, prescribed secondary prophylaxis)
171 (18.7%)
n (%) unless otherwise indicated. ARF indicates acute rheumatic fever; 
and BPG, benzathine penicillin G.
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with shorter than recommended11 durations in 17% 
of cases based on presenting features and severity of 
cardiac involvement. Together, these data suggest that 
increased clinician and parental education is needed 
to ensure that children living with ARF and RHD in the 
United States receive guideline- based care.
Finally, these data support that RHD remains a dis-
ease characterized by inequity among children living 
in the United States. Greater community socioeco-
nomic deprivation was associated with having more 
severe valvular involvement, which could reflect living 
conditions such as overcrowding, poor sanitation, 
and poor hygiene, which are long recognized factors 
that increase exposure to group A streptococcal dis-
ease.13,38,39 It is worth noting that this finding contrasts 
that of a recent study on children hospitalized for ARF, 
finding no statistically significant differences in socio-
economic status. That study, however, was limited by 
its sole use of insurance status as a proxy for socioeco-
nomic status.5 The deprivation index provides a more 
multidimensional assessment of one’s contextual living 
environment, and our conclusions support the findings 
that ARF and RHD outcomes remain inequitable glob-
ally and nationally.1
Limitations
There are several limitations in our data stemming from 
our pragmatic recruitment strategy based on tertiary 
hospital programs. First, our data may not be represent-
ative of patients and clinical practices outside of major 
Table 5. Echocardiographic Data
All (n=947) Acute Rheumatic Fever (n=684) Rheumatic Heart Disease (n=258)
Echocardiogram performed 917 (96.8%) 656 (95.9%) 258 (100%)
Mitral stenosis 73 (8.0%) 24 (3.7%) 49 (19.0%)
Mild 38 (52.0%) 17 (70.8%) 21 (42.8%)
Moderate 21 (28.8%) 5 (20.8%) 16 (32.7%)
Severe 6 (8.2%) 1 (4.2%) 5 (10.2%)
Data on quantification not available 8 (11.0%) 1 (4.2%) 7 (14.3%)
Mitral regurgitation 645 (70.3%) 417 (63.6%) 228 (88.4%)
< Moderate 277 (42.9%) 206 (49.4%) 71 (31.1%)
Moderate 219 (34.0%) 137 (32.8%) 82 (36.0%)
Severe 144 (22.3%) 72 (17.3%) 72 (31.6%)
Data on quantification not available 5 (0.8%) 2 (0.5%) 3 (1.3%)
Aortic stenosis 21 (2.3%) 3 (0.5%) 18 (7.0%)
< Moderate 17 (80.9%) 2 (66.7%) 15 (83.3%)
Moderate 3 (14.3%) 1 (33.3%) 2 (11.1%)_
Severe 0 (0%) 0 (0%) 0 (0%)
Data on quantification not available 1 (4.8%) 0 (0%) 1 (5.6%)
Aortic regurgitation 352 (38.4%) 221 (33.7%) 131 (50.8%)
< Moderate 191 (54.3%) 136 (61.5%) 55 (42.0%)
Moderate 102 (29.0%) 58 (26.2%) 44 (33.6%)
Severe 55 (15.6%) 24 (10.9%) 31 (23.7%)
Data on quantification not available 4 (1.1%) 3 (1.4%) 1 (0.7%)
Pulmonary hypertension 66 (7.2%) 27 (4.1%) 39 (15.1%)
Reduced left ventricular systolic 
function
27 (2.9%) 10 (1.5%) 17 (6.6%)
Mildly reduced 16 (59.3%) 6 (60.0%) 10 (58.8%)
Moderately reduced 7 (25.9%) 2 (20.0%) 5 (29.4%)
Severely reduced 4 (14.8%) 2 (20.0%) 2 (11.8%)
Reduced right ventricular systolic 
function
9 (1.0%) 2 (0.3%) 7 (2.7%)
Pericardial effusion 81 (8.8%) 51 (7.8%) 30 ( 11.6%)
Trace/small 66 (87.6%) 40 (78.4%) 26 (86.7%)
Moderate 9 (6.7%) 7 (13.7%) 2 (6.7%)
Large 4 (3.8%) 3 (5.9%) 1 (3.3%)
Present but not quantified 2 (1.9%) 1 (2.0%) 1 (3.3%)
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Table 6. Disease Severity
Mild (n=452) Moderate (n=188) Severe (n=232) P value
Sex 0.03
Male 245 (54.2%) 98 (52.1%) 101 (43.5%)
Female 207 (45.8%) 90 (47.9%) 131 (56.5%)
N=436 N=180 N=222
Age at diagnosis, y, median (interquartile range) 9 (7– 12) 10 (8– 12) 10 (7– 13) 0.11
Race <0.001
American Indian or Alaska Native 17 (3.8%) 14 (7.4%) 8 (3.4%)
Asian 14 (3.1%) 9 (4.8%) 17 (7.3%)
Black 58 (12.8%) 37 (19.7%) 61 (26.3%)
Native Hawaiian or other Pacific Islander 30 (6.6%) 11 (5.9%) 24 (10.3%)
White 235 (52.0%) 80 (42.6%) 71 (30.6%)
Other 64 (14.2%) 23 (5.1%) 39 (16.8%)
Unknown 34 (7.5%) 14 (7.4%) 12 (5.2%)
Ethnicity 0.79
Hispanic or Latino 73 (16.2%) 29 (15.4%) 42 (18.1%)
Non- Hispanic or Latino 339 (75.0%) 139 (73.9%) 172 (74.1%)
Unknown 40 (8.8%) 20 (10.6%) 18 (7.8%)
Primary language 0.001
English 392 (86.7%) 155 (82.4%) 183 (78.9%)
Spanish 36 (8.0%) 20 (10.6%) 18 (7.8%)
Other 17 (3.8%) 13 (6.9%) 28 (12.1%)
Unknown 7 (1.5%) 0 (0%) 3 (1.3%)
N=436 N=176 N=226
Has health insurance 407 (90.0%) 165 (87.8%) 206 (88.8%) 0.51
N=399 N=170 N=222
Type of health insurance 0.64
Private 167 (36.9%) 69 (36.7%) 79 (34.1%)
Medicaid or Medicare 201 (44.5%) 90 (47.9%) 123 (53.0%)
Both 2 (0.4%) 0 (0%) 0 (0%)
Unknown 37 (8.2%) 6 (3.2%) 4 (1.7%)
Diagnosed in the United States 0.09
Yes 381 (84.3%) 164 (87.2%) 186 (80.2%)
No 54 (11.9%) 18 (9.6%) 38 (16.4%)
Unknown 17 (3.8%) 6 (3.2%) 8 (3.4%)
N=354 N=161 N=182
Parent primary language English 297 (65.7%) 133 (70.7%) 137 (59.1%) 0.047
Travel exposure before diagnosis 0.02
Yes 65 (14.4%) 29 (15.4%) 53 (22.8%)
No 68 (15.0%) 32 (17.0%) 45 (19.4%)
Unknown 319 (70.6%) 127 (67.6%) 134 (57.8%)
Travel to endemic region 49 (10.8%) 25 (13.3%) 45 (19.4%) 0.31
Prescribed secondary prophylaxis 0.43
Yes 437 (96.7%) 181 (96.3%) 224 (96.6%)
No 9 (2.0%) 7 (3.7%) 5 (2.2%)
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medical centers. Second, although we invited par-
ticipation from all programs with a pediatric cardiology 
fellowship, only 37% of invited institutions participated. 
Although we recruited nearly 1000 patients, increasing 
the internal validity of our data, there were some geo-
graphic areas of our country that were not well repre-
sented, such as the West, and thus certain populations 
may be underrepresented or not captured. Given this, 
we could not compare population characteristics, such 
as race or ethnicity, to overall US population characteris-
tics to confidently identify groups at higher risk.
Retrospective review of data led to several addi-
tional limitations. Data on travel to an endemic re-
gion did not include specifications on the nature of 
exposure (for example, limited travel exposure ver-
sus prior residence in endemic region); thus we are 
unable to comment on whether participants were 
immigrants from an endemic region or merely went 
to visit. We collected echocardiographic data only 
at presentation and are not able to comment on the 
longitudinal progression or regression of cardiac dis-
ease. In addition to our population limitations, DI is a 
measure of community- level deprivation and cannot 
be used to extrapolate individual risk prediction and 
we cannot rule out the potential for unmeasured fac-
tors to have resulted in residual confounding when 
estimating the association between neighborhood 
deprivation and outcomes of interest.
CONCLUSIONS
ARF and RHD are characterized by equity gaps in the 
United States as well as around the world. Children 
who newly acquire ARF and RHD in the United States 
are, for the most part, exposed to group A strepto-
coccal disease and experiencing the sequelae within 
the United States and not abroad. There is room to 
improve evidence- based treatment for ARF and RHD 
in the United States, both through provider and par-
ent education. Further study of high- risk popula-
tions in the United States could better target these 
educational efforts and provide the opportunity to 
strengthen primary prevention for our most vulner-
able children.
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Table S1. Participant Enrollment by Site. 
Site Total Enrolled (n) 
Duke Children’s Hospital & Health Center 7 
Nicklaus Children’s Hospital 7 
University of Florida Health, Shands Children’s Hospital 11 
Yale New Haven Medical Center 17 
Morgan Stanley Children’s Hospital of New York 
Presbyterian, Columbia University Medical Center 
17 
Nationwide Children’s Hospital 19 
University of Mississippi 21 
Children’s Mercy Hospital 23 
University of Rochester Medical Center 26 
University of Arkansas for Medical Sciences  31 
University of New Mexico 34 
Washington University School of Medicine, St. Louis 39 
Ann & Robert H. Lurie Children’s Hospital of Chicago 41 
Monroe Carell Jr Children’s Hospital at Vanderbilt 45 
Children’s Healthcare of Atlanta, Emory University 49 
Texas Children’s Hospital 52 
Nemours.Alfred I. DuPont Hospital for Children 56 
Children’s Hospital at Montefiore 67 
Boston Children’s Hospital 72 
Children’s National Hospital 80 
Cincinnati Children’s Hospital Medical Center 101 
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